- Report
- November 2024
Global
From €400EUR$431USD£344GBP
- Report
- November 2024
Global
From €300EUR$323USD£258GBP
- Report
- March 2023
- 71 Pages
Global
From €480EUR$518USD£413GBP
- Report
- August 2021
- 50 Pages
United States
From €2384EUR$2,400USD£1,982GBP
- Report
- March 2021
- 240 Pages
United States
From €2980EUR$3,000USD£2,478GBP
- Report
- December 2020
- 120 Pages
Global
From €1987EUR$2,000USD£1,652GBP
- Report
- May 2021
- 358 Pages
Global
From €1366EUR$1,375USD£1,136GBP
€2732EUR$2,750USD£2,272GBP
- Report
- July 2022
- 461 Pages
Global
From €4917EUR$5,123USD£3,950GBP
- Report
- June 2023
- 298 Pages
Global
From €4918EUR$4,950USD£4,089GBP
- Report
- October 2023
- 85 Pages
United States
From €4818EUR$4,850USD£4,006GBP
- Report
- September 2023
- 76 Pages
Global
From €4918EUR$4,950USD£4,089GBP
- Report
- July 2023
- 70 Pages
Global
From €5911EUR$5,950USD£4,915GBP
- Report
- January 2023
- 306 Pages
Global
From €4172EUR$4,200USD£3,469GBP
- Newsletter
- November 2024
- 4 Pages
Global
From €199EUR$200USD£165GBP
- Report
- May 2019
- 67 Pages
Global
€2975EUR$2,995USD£2,474GBP
- Report
- August 2022
- 180 Pages
Global
From €2186EUR$2,200USD£1,817GBP
- Report
- October 2023
- 150 Pages
Global
From €4818EUR$4,850USD£4,006GBP
- Report
- August 2023
- 205 Pages
Europe
From €2086EUR$2,100USD£1,735GBP
€2980EUR$3,000USD£2,478GBP
- Report
- February 2023
- 217 Pages
Global
From €3164EUR$3,185USD£2,631GBP
€4520EUR$4,550USD£3,758GBP
- Report
- December 2019
- 120 Pages
Global
From €3676EUR$3,700USD£3,056GBP
The Biosimilars and Biosuperiors market is a rapidly growing sector of the pharmaceutical industry. Biosimilars are biologic drugs that are highly similar to an existing biologic drug, while biosuperiors are biologic drugs that are more effective than an existing biologic drug. Biosimilars and biosuperiors are used to treat a variety of conditions, including cancer, autoimmune diseases, and inflammatory diseases.
Biosimilars and biosuperiors are developed using advanced biotechnology techniques, such as recombinant DNA technology and monoclonal antibody technology. These drugs are designed to be more cost-effective than their original counterparts, while still providing the same therapeutic benefits.
The Biosimilars and Biosuperiors market is expected to continue to grow in the coming years, as more biologic drugs are developed and approved for use. Companies in this market include Amgen, Pfizer, Merck, and Novartis. Show Less Read more